140 related articles for article (PubMed ID: 35179241)
1. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
Ball S; Jain AG; Aguirre LE; Al Ali N; Zhang Y; Chan O; Kuykendall AT; Sweet KL; Lancet JE; Swoboda DM; Padron E; Komrokji RS; Sallman DA
Am J Hematol; 2022 May; 97(5):E185-E188. PubMed ID: 35179241
[No Abstract] [Full Text] [Related]
2. Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia.
Saliba AN; Litzow MR; Gangat N; Al-Kali A; Foran JM; Hogan WJ; Palmer JM; Mangaonkar AA; Tefferi A; Patnaik MM
Am J Hematol; 2021 Nov; 96(11):E433-E436. PubMed ID: 34428328
[No Abstract] [Full Text] [Related]
3. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
Montalban-Bravo G; Hammond D; DiNardo CD; Konopleva M; Borthakur G; Short NJ; Ramos-Perez J; Guerra V; Kanagal-Shamanna R; Naqvi K; Sasaki K; Jabbour E; Pemmaraju N; Kadia TM; Ravandi F; Daver N; Estrov Z; Pierce S; Kantarjian H; Garcia-Manero G
Leukemia; 2021 May; 35(5):1494-1499. PubMed ID: 33846541
[No Abstract] [Full Text] [Related]
4. The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
Lim B; Yoo D; Chun Y; Go A; Cho KJ; Choi D; Jung ME; Lee HY; Boohaker RJ; Lee JS; Jung D; Choi G
Blood Cancer J; 2022 Apr; 12(4):57. PubMed ID: 35410412
[No Abstract] [Full Text] [Related]
5. Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series.
Garcia-Horton A; Maze D; McNamara CJ; Sibai H; Gupta V; Murphy T
Leuk Lymphoma; 2021 Jun; 62(6):1525-1527. PubMed ID: 33448888
[No Abstract] [Full Text] [Related]
6. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.
Gangat N; Johnson I; McCullough K; Farrukh F; Al-Kali A; Alkhateeb H; Begna K; Mangaonkar A; Litzow M; Hogan W; Shah M; Patnaik M; Pardanani A; Tefferi A
Haematologica; 2022 Oct; 107(10):2501-2505. PubMed ID: 35770533
[No Abstract] [Full Text] [Related]
7. The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement.
Otoukesh S; Zhang J; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V; Aldoss I
Leuk Lymphoma; 2020 Aug; 61(8):2020-2023. PubMed ID: 32191144
[No Abstract] [Full Text] [Related]
8. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Ferrara F
Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
[No Abstract] [Full Text] [Related]
9. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
[TBL] [Abstract][Full Text] [Related]
10. Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents.
Zainaldin C; Arora S; Bathini S; Gupta U; Pandya V; Bae S; Worth S; Bachiashvili K; Bhatia R; Godby K; Jamy O; Rangaraju S; Diamond B; Oliver JD; Salzman D; Di Stasi A; Vachhani P
Leuk Lymphoma; 2022 Dec; 63(13):3245-3248. PubMed ID: 36107006
[No Abstract] [Full Text] [Related]
11. Hypomethylating agents with venetoclax: have we discovered the holy grail?
Gutman JA; Pollyea DA
Curr Opin Hematol; 2020 Mar; 27(2):76-80. PubMed ID: 31895103
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
Jamy O; Lin K; Worth S; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R
Br J Haematol; 2022 Aug; 198(3):e35-e37. PubMed ID: 35509246
[No Abstract] [Full Text] [Related]
13. How to discover the exceptional venetoclax responders in AML/MDS?
Gjertsen BT
Br J Haematol; 2024 Jan; 204(1):14-15. PubMed ID: 37920123
[No Abstract] [Full Text] [Related]
14. Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm.
Gangat N; Ilyas R; McCullough K; Begna KH; Al-Kali A; Patnaik MM; Litzow MR; Hogan WJ; Mangaonkar A; Alkhateeb H; Shah MV; Elliott MA; Foran JM; Badar T; Palmer JM; Hanson CA; Pardanani A; Tefferi A
Haematologica; 2023 May; 108(5):1423-1428. PubMed ID: 36519330
[No Abstract] [Full Text] [Related]
15. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia.
Kennedy VE; Hui G; Azenkot T; Gaut D; Wieduwilt MJ; Oliai C; Jonas BA; Mittal V; Logan AC; Muffly LS; Mannis GN
Am J Hematol; 2022 Jun; 97(6):E191-E194. PubMed ID: 35266185
[No Abstract] [Full Text] [Related]
16. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome.
Komrokji RS; Singh AM; Ali NA; Chan O; Padron E; Sweet K; Kuykendall A; Lancet JE; Sallman DA
Blood Cancer J; 2022 Nov; 12(11):148. PubMed ID: 36329025
[No Abstract] [Full Text] [Related]
17. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
18. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
Hammond D; Loghavi S; Wang SA; Konopleva MY; Kadia TM; Daver NG; Ohanian M; Issa GC; Alvarado Y; Short NJ; Sasaki K; Pemmaraju N; Montalban-Bravo G; Lachowiez CA; Maiti A; Garcia-Manero G; Jabbour EJ; Borthakur G; Ravandi F; Takahashi K; Pierce SR; Kantarjian HM; DiNardo CD
Blood Cancer J; 2023 Sep; 13(1):148. PubMed ID: 37735426
[No Abstract] [Full Text] [Related]
19. Venetoclax in AML: Where We Are and Where We Are Headed.
Pollyea DA
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S25-S26. PubMed ID: 32862856
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
Maiti A; Rausch CR; Cortes JE; Pemmaraju N; Daver NG; Ravandi F; Garcia-Manero G; Borthakur G; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Kadia TM; Takahashi K; Yilmaz M; Jain N; Kornblau S; Montalban Bravo G; Sasaki K; Andreeff M; Bose P; Ferrajoli A; Issa GC; Jabbour EJ; Masarova L; Thompson PA; Wang S; Konoplev S; Pierce SA; Ning J; Qiao W; Welch JS; Kantarjian HM; DiNardo CD; Konopleva MY
Haematologica; 2021 Mar; 106(3):894-898. PubMed ID: 32499238
[No Abstract] [Full Text] [Related]
[Next] [New Search]
